Evidence map›Paper›PMID 42424572›Full record

ReviewNeurology. Clinical practice2026

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Pushpa Narayanaswami, Renato Mantegazza, Carolina Barnett-Tapia, Elena Cortés-Vicente, Miriam L Freimer, Nils Erik Gilhus, Ali A Habib, James F Howard, Anna Kostera-Pruszczyk, M Isabel Leite and 9 more

Abstract readConsensus StatementReview
In one paragraph

Review in Neurology. Clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Pushpa NarayanaswamiDepartment of Neurology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.ORCID 0000-0002-9412-7349
Renato MantegazzaDepartment of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy.ORCID 0000-0002-9810-5737
Carolina Barnett-TapiaEllen and Martin Prosserman Centre for Neuromuscular Diseases, Toronto General Hospital, University of Toronto, Ontario, Canada.ORCID 0000-0001-5546-0221
Elena Cortés-VicenteNeuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0002-1428-1072
Miriam L FreimerDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus.ORCID 0000-0001-8282-764X
Nils Erik GilhusDepartment of Neurology, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0001-6522-5102
Ali A HabibMDA ALS & Neuromuscular Center, Department of Neurology, University of California, Irvine, Orange.ORCID 0000-0003-3432-9747
James F HowardDepartment of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Anna Kostera-PruszczykDepartment of Neurology, Medical University of Warsaw, ERN EURO-NMD, Warsaw, Poland.ORCID 0000-0002-7309-1914
M Isabel LeiteNuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom.ORCID 0000-0002-4277-9855
Andreas MeiselDepartment of Neurology and Experimental Neurology, Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, Germany.ORCID 0000-0001-7233-5342
Mamatha PasnoorDepartment of Neurology, University of Kansas Medical Center, KS.ORCID 0000-0001-7424-4719
Sabrina SacconiUniversité Côte d'Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, France.ORCID 0000-0002-0246-1455
Nicholas J SilvestriDepartment of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY.ORCID 0000-0001-7931-0930
Julia StevensOgilvy Health, London, United Kingdom.ORCID 0009-0004-8681-2081
Shigeaki SuzukiDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Japan.ORCID 0000-0003-4388-4574
Akiyuki UzawaDepartment of Neurology, Graduate School of Medicine, Chiba University, Japan; and.ORCID 0000-0001-9252-1863
Gil I WolfeDepartment of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY.ORCID 0000-0003-1471-9617
Kimiaki UtsugisawaDepartment of Neurology, Hanamaki General Hospital, Japan.ORCID 0000-0001-9373-8167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesGoals for comprehensive care are important in the management of individualized treatment for patients with myasthenia gravis (MG), a disease with variable presentation and degrees of severity. Yet there is limited guidance on how comprehensive care should be achieved and implemented. We present global consensus recommendations for comprehensive care of patients with MG.

methodsAn international panel of experts was formed, and a targeted literature review was conducted to inform the recommendations. A steering committee selected relevant topics and draft recommendations were developed for each topic. Formal consensus was achieved using the RAND/UCLA appropriateness method. Seventeen panelists from North America, Europe, and Asia rated statements online from 1 ("extremely inappropriate") to 9 ("extremely appropriate") and provided comments and suggestions for modifications. The methodologist modified statements for further rating, based on panel scores and feedback. Statements achieving agreement as appropriate by 4 rounds of rating were accepted.

resultsConsensus was achieved for 21 statements. Statement 1 defined the ongoing treatment goal: "to work toward, achieve, and sustain minimal symptoms and treatment-related adverse events, with a patient-acceptable quality of life (using validated measures)". Subsequent statements described implementation of this goal and covered: early control of symptoms; establishing and sustaining a treatment goal; vaccination and screening for infection; family planning/pregnancy; management of fatigue and comorbidities; and management of impending crisis and crisis. DISCUSSION: Expert consensus was achieved on a series of global recommendations for comprehensive care goals, which has implications for improved disease outcomes and health-related quality of life for patients with MG. These recommendations will require updating as treatment paradigms evolve.

Indexed as

Comprehensive Health CareMyasthenia GravisHumans

Identifiers

PMID42424572
PMCPMC13352217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.